BOSTON & GENEVA -- (BUSINESS WIRE) -- Celgene Corporation used the PHT Corporation SitePad® System to collect primary and secondary endpoints for studies of its Otezla (apremilast) drug which the FDA approved in March 2014 to treat adults with active psoriatic arthritis (PsA).
PHT is the leading provider of technologies used to collect patient-driven eData for clinical research. The PHT SitePad System includes a large-screen mobile tablet for capturing study-specific clinician and patient assessments at the investigative site. Real-time access to all the data collected is available in StudyWorks™, the PHT online portal for data review and management. Using the SitePad System helps to increase the quality of the data collected, the time to database lock and reduces monitoring time and costs.
The safety and effectiveness of Otezla, an oral inhibitor of phosphodieasterase-4 (PDE-4), were evaluated in three clinical trials involving 1,493 patients with active PsA. Patients treated with Otezla showed improvement in signs and symptoms of PsA, including tender and swollen joints and physical function, compared to placebo.
PHT President and CEO Philip Lee said, “PHT is honored to have been a part of this development program which has resulted in success for Celgene and patients suffering from PsA around the globe. The PHT team members who worked on this project are gratified both personally and professionally to be part of bringing this important new therapy to market.”
About PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 650+ trials resulting in 16+ regulatory approvals. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Twitter, Google+ and YouTube.